Compare VRAX & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | TXMD |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 25.9M |
| IPO Year | 2021 | 2012 |
| Metric | VRAX | TXMD |
|---|---|---|
| Price | $0.17 | $2.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 161.6K | 19.6K |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.61 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $217,274.83 | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.64 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.18 | $0.83 |
| 52 Week High | $1.35 | $2.95 |
| Indicator | VRAX | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 48.54 |
| Support Level | N/A | $2.10 |
| Resistance Level | $0.25 | $2.35 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.46 | 57.14 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.